Clinical Trials Logo
  1. Home
  2. Leishmaniasis
  3. NCT06307171

Human Leishmaniasis: Antigen Recognition Pattern and Study of New Potential Biomarkers — LeishmARPs  

Leishmaniasis Clinical Trial

Official title:
Human Leishmaniasis: Antigen Recognition Pattern and Study of New Potential Biomarkers

Clinical Trial Summary

This is an exploratory experimental multicentre study on archived serum samples and on prospectively collected serum samples and blood samples. General objectives of the study are: to identify specific biomarkers in order to develop more accurate serological tests for the screening of Leishmania infections that does not present cross-reaction with other infectious diseases; to unveil the Antigen Recognition Patterns (ARPs) of Leishmania infection in humans; to verify whether the ARPs and the new biomarkers are common to different Leishmania infantum strains isolated in Italy as well as in other part of the World and to different strains of L. donovani isolated in Sudan as well as in other part of the World and discard any possible cross reaction with other infectious diseases such as Chagas, TB, leprosy or malaria.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06307171
Study type Interventional
Source IRCCS Sacro Cuore Don Calabria di Negrar
Contact
Status Recruiting
Phase N/A
Start date May 22, 2023
Completion date November 2026
View Details
See also
  Status Clinical Trial Phase
Completed NCT03641339 - Defining Skin Immunity of a Bite of Key Insect Vectors in Humans N/A
Completed NCT04504435 - Safety, Tolerability and Pharmacokinetics (PK) Investigation of GSK3494245 in Healthy Participants Phase 1
Completed NCT00004755 - Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil Phase 2
Completed NCT00657618 - Use of Sodium Stibogluconate as a Treatment for Leishmaniasis Phase 1/Phase 2
Completed NCT04512742 - A Clinical Study to Develop a Controlled Human Infection Model Using Leishmania Major-infected Sand Flies N/A
Recruiting NCT00344188 - Diagnosis and Treatment of Leishmania Infections
Active, not recruiting NCT03009422 - Fractional CO2 Laser With Topical Pentostam Treatment for Cutaneous Leishmaniasis. N/A
Recruiting NCT05449717 - Incidence of Relapse and Post-Kala-Azar Dermal Leishmaniasis in South Sudan
Completed NCT01751048 - LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine Phase 1
Terminated NCT06124144 - Safety and Drug Absorption of Orally Administered Oleylphosphocholine (OlPC) in Healthy Adults Phase 1
Completed NCT00662012 - Sodium Stibogluconate Treatment of Leishmaniasis Phase 2
Completed NCT03993093 - Prevalence of HIV +ve Cases With AIDS Defining Opportunistic Infections Among ART Naive Patients Attending ART Centre
Recruiting NCT03784248 - Mediterranean Visceral Leishmaniasis With Leishmania Infantum
Withdrawn NCT02429505 - Treatment of Leishmaniasis With Impavido® (Miltefosine): Higher-Weight Patient Registry
Completed NCT01377974 - Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis Phase 2
Completed NCT02656797 - Topical Liposomal Amphotericin B Gel Treatment for Cutaneous Leishmaniasis Phase 2
Completed NCT01484548 - Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult Volunteers Phase 1
Completed NCT01300975 - Intralesional Antimony for Bolivian Cutaneous Leishmaniasis Phase 2
Completed NCT03294161 - Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis Phase 2
Completed NCT00401557 - Mechanisms Relating to the Distinct in Vitro Susceptibility of Human Macrophages to L. Viannia Infection